En respuesta a la aparición de nuevas pruebas científicas, la OMS está desarrollando una serie revisada y consolidada de directrices relacionadas con el uso de terapias antirretrovirales para el tratamiento y prevención del VIH, dando prioridad a las personas que se encuentran en situación de mayor riesgo. Más información, en inglés, está disponible abajo.

Suscríbase a las Alertas mensuales del IDPC para recibir información sobre cuestiones relacionadas con políticas sobre drogas.


Help make sure the voices of civil society and communities are heard in determining which ARVs are available and how they are provided in the future

What are the guidelines?

Responding to the emergence of new scientific evidence, WHO is in the process of developing a revised and consolidated set of guidelines related to the use of ARVs for HIV treatment and prevention, prioritising people who are most at risk and aiming to accelerate progress towards universal access to HIV diagnostics, treatment, care and support. The guidelines are planned for release in early 2013 - previous versions can be found here.

What is the consultation?

The new generation of guidelines will include in addition to the customary clinical guidance, operational and service delivery guidance and programmatic guidance targeted towards HIV programme managers, which will help countries make the best strategic decisions on the use of ARVs.

Recognising it is critical the guidelines reflect the realities of the lives of people and communities living with and affected by HIV, and of civil society, WHO seeks to undertake a consultative process with communities to inform these revised, consolidated guidelines.

To support communities’ active role in informing the revised, consolidated guidelines the International HIV/AIDS Alliance and GNP+, in collaboration with WHO, will conduct an online e-survey (7tt November - 21st December) and an online e-forum discussion (12th November – 21st December).A Civil Society Working Group has been formed to guide the content and process of consultation and promote effective and inclusive engagement of communities.

How can I take part?

Opportunities to feed into the process will take place between 7th November and early January 2013 and will include:

  • An online survey available in five languages: English, French, Spanish, Russian, and Arabic. This will be online from 7th November 2012 to 14th January 2013
  • E-Forum discussions providing opportunities for more in-depth qualitative discussions around key technical issues and areas of concern (Starting and end date)

To stay informed, and get ready for the consultation, please sign up for our consultation eForum discussions by sending a blank email to the following e-mail address:

Keep up-to-date with drug policy developments by subscribing to the IDPC Monthly Alert.